Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine

T Nolan; ME Santolaya; F de Looze; H Marshall; P Richmond; S Henein; P Rheault; K Heaton; KP Perrett; H Garfield; A Gupta; M Ferguson; D D'Agostino; D Toneatto; M O'Ryan

Journal article

Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine

T Nolan, ME Santolaya, F de Looze, H Marshall, P Richmond, S Henein, P Rheault, K Heaton, KP Perrett, H Garfield, A Gupta, M Ferguson, D D'Agostino, D Toneatto, M O'Ryan

Vaccine | ELSEVIER SCI LTD | Published : 2019

DOI: 10.1016/j.vaccine.2018.12.059

Abstract

Background: Data on duration of protection against invasive meningococcal disease post-vaccination with the recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) are limited. We evaluated bactericidal activity persistence in adolescents/young adults up to 7.5 years post-primary vaccination with 4CMenB, and response to a booster dose compared with vaccine-naïve controls. Methods: This open-label, multicenter study (NCT02446743) enrolled 15–24 year-old-previously vaccinated participants from Canada, Australia (group Primed_4y) 4 years post-priming with 4CMenB (2 doses; 0,1-month schedule), and Chile (Primed_7.5y) 7.5 years after priming with 4CMenB (2 doses; 0,1/0,2/0,6-month sc..

View full abstract

University of Melbourne Researchers

Terry Nolan Author

Kirsten Perrett Author

Grants

Funding Acknowledgements

This study was funded by Novartis Vaccines and Diagnostics Inc., now part of the GSK group of companies. GlaxoSmithKline Biologicals SA took responsibility for all costs associated with the development and publishing of the present manuscript.